Investors
Creating value for stakeholders
We are an established, commercial-stage diagnostics company.
We are an established, commercial-stage diagnostics company with over 30 years’ experience of manufacturing and supplying the conventional reagent products used for blood grouping within the $3.4 billion global transfusion diagnostics market.
Our proprietary technology platform, MosaiQ, is continually been developed and enhanced to better address the comprehensive needs of this large and established market. We believe MosaiQ has the potential to be a transformative technology that significantly reduces the cost of blood grouping in both donor and patient-testing environments.
Investors
4:00 PM EDT • Jun 30, 2022
QTNT
0.24USD
-3.03%
Contact
Ali Kiboro, Chief Financial Officer
IR@quotientbd.com
3 Months
6 Months
12 Months
Quotient Ltd
$
Events & presentations
Quotient Limited to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call
ISBT 2022 Virtual Congress
Our reagents by Quotient
Alba by Quotient. Experience. Expertise. Value.
These are just some of the qualities that set us apart from the competition. You can have peace of mind using our products, which have been time-tested for more than 30 years.